<DOC>
	<DOCNO>NCT01459809</DOCNO>
	<brief_summary>Primary Objective : - To demonstrate superiority glimepiride metformin free combination comparison glimepiride metformin alone term Hb1Ac reduction 24-week treatment period patient type 2 diabetes mellitus . Secondary Objectives : - To assess effect free combination glimepiride metformin comparison glimepiride metformin alone : - Percentage patient reach HbA1c &lt; 7 % - Percentage patient reach HbA1c &lt; 6.5 % - Fasting Plasma Glucose ( FPG ) - Safety tolerability</brief_summary>
	<brief_title>Efficacy Safety Comparison Metformin/Glimepiride Combination Versus Each Compound Alone New Diagnosed Type 2 Diabetes Patients</brief_title>
	<detailed_description>The study duration patient approximately 27 week 3 period : 2-week screening period follow 24-week treatment period patient assign one three arm accord randomization , 3 day follow-up period last call phone visit .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion Patients type 2 diabetes mellitus , define World Health Organization ( WHO ) , diagnose within one year prior screen visit Signed informed consent , obtain prior study procedure Exclusion criterion Age &lt; 18 = &gt; 78 year old HbA1c &lt; 7.6 % &gt; 9 % BMI &gt; 35 kg/m2 Diabetes type 2 diabetes ( e.g . : type 1 diabetes , diabetes secondary pancreatic disorder , drug chemical agent intake ... ) Subjects currently receive receive hypoglycemic agent within 3 month screen visit The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>